Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Integrating Somatic and Germline Pharmacogenomics for Therapeutic Decisions in Precision Oncology.

JCO precision oncology - 1 May 2026

Pathak Vai S, Hershberger Courtney E, Kamath Suneel, Williams Porscha Johnson, Rhodes Terence D, McLeod Howard L, Rotroff Daniel M

Abstract excerpt

PURPOSE: Clinical genomic profiling of tumors identifies therapeutic targets, while germline pharmacogenomics (PGx) guides drug dosing and toxicity avoidance. However, the combined clinical landscape of both somatic and germline actionable variants across cancers has not been comprehensively defined. METHODS: Tumor and matched germline whole-exome sequencing data were analyzed for 10,302 patients in The Cancer...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Aged
Share to Antineoplastic Agents

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Exome Sequencing

Share to Germ-Line Mutation

Share to Medical Oncology

Share to Neoplasms

Share to Pharmacogenetics

Share to Precision Medicine

Source

Open in PubMed Open full text

Identifiers

PMID: 42090628
DOI: 10.1200/PO-25-01238
PMCID: PMC13155219

Genes

CYP2C19
CYP2C9
DPYD
KRAS
PIK3CA
UGT1A1

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 2 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Integrating Somatic and Germline Pharmacogenomics for Therapeutic Decisions in Precision Oncology.PMID 42090628Read ↗

Modern developments in germline pharmacogenomics for oncology prescribingSemantic proximity Read ↗

Innovation in cancer pharmacotherapy through integrative consideration of germline and tumor genomesSemantic proximity Read ↗

Integrating pharmacogenomic testing into paired germline and somatic genomic testing in patients with cancer.Semantic proximity Read ↗

Cancer pharmacogenomics, challenges in implementation, and patient-focused perspectivesSemantic proximity Read ↗

Pan-cancer pharmacogenetics: targeted sequencing panels or exome sequencing?Semantic proximity Read ↗

CLINICAL OPPORTUNITIES FOR GERMLINE PHARMACOGENETICS AND MANAGEMENT OF DRUG-DRUG INTERACTIONS IN PATIENTS WITH ADVANCED SOLID CANCERSSemantic proximity Read ↗

Clinical Opportunities for Germline Pharmacogenetics and Management of Drug-Drug Interactions in Patients With Advanced Solid CancersSemantic proximity Read ↗

Assessing actionability and incidental findings of germline variants in two precision oncology trials.Semantic proximity Read ↗

Comparison of actionable events detected in cancer genomes by whole-genome sequencing, in silico whole-exome and mutation panels.Semantic proximity Read ↗

Development and clinical application of an integrative genomic approach to personalized cancer therapy.Semantic proximity Read ↗

Use of pharmacogenetics for predicting cancer prognosis and treatment exposure, response and toxicity.Semantic proximity Read ↗

Personalized genomic analyses for cancer mutation discovery and interpretation.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.